SBIR/STTR Research Award
HIV REV DEPENDENT REPORTER CELL FOR NEUTRALIZING ANTIBODY DISCOVERY
Award amount
$216,675Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Virongy L.L.C.
- Proposal award date
- 2017-08-07
- Contract end date
- 2019-01-31
- UEI
- K58UC9NJFSZ3
- Solicitation number
- PA16-302
- Topic code
- NIAID
Research abstract
The development of an effective vaccine is the most plausible approach to eliminate the HIV AIDS
pandemic The detection of broadly neutralizing antibody bNABs responses is critical for vaccine
development In this grant application we propose to develop a novel sensitive method for bNAB
detection and quantification An HIV Rev dependent A R derived reporter cell line Rev A R
NanoLuc HaloTag A R is a T lymphoblast that expresses physiologically relevant levels of the
HIV receptors CD and CXCR CCR and is highly susceptible to X and R viruses A R has
also been shown to be the optimal cell line currently available for bNAB detection We plan to
engineer A R to carry two highly sensitive reporters NanoLuc the most sensitive luciferase
currently available and HaloTag the most flexible fluorescent reporter Both reporters are engineered
to exclusively depend on HIV and Rev for expression eliminating non specific noises from
environmental stimuli This novel system will provide unmatched specificity and sensitivity
providing a new standard for NABs detection and quantification We plan to carry out two specific
aims in the phase I stage
Aim will be to create a high sensitivity A R derived Rev dependent reporter cell line Rev
A R for bNAB detection We will first construct the Rev dependent vector pNL NanoLuc HaloTag
RRE for assembly into lentiviral viral particles which will be used to transduce A R cells Subclones
will be selected for optimal performance in NAB detection
Aim will be to characterize and validate Rev A R We will test the specificity of the reporter
cells Additionally Rev A R andapos s susceptibility to primary viral isolates will be tested We will also
perform bNAB screen using a panel of antibodies and patient sera to optimize the system for Phase II
development
We aim to develop the system into a standard assay product for academic and industry laboratories
for bNAB screening and validation The detection of HIV broadly neutralizing antibodies bNAB is critical for vaccine development In this
grant application we propose to develop a novel sensitive reporter cell line for bNAB detection and
quantification This novel system will offer unmatched specificity and sensitivity providing a new
standard for academic and industry laboratories for bNAB screening and validation
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients